A Novel Approach to Assess the Potency of Topical Corticosteroids.
Emax model
active pharmaceutical ingredients
chromameter
potency
skin blanching response
topical corticosteroids
vasoconstrictor assay
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
13 Sep 2021
13 Sep 2021
Historique:
received:
02
07
2021
revised:
11
08
2021
accepted:
26
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
The potencies of topical corticosteroid products have mainly been classified using clinical data but in some instances, the US Food and Drug Administration's (FDA's) vasoconstrictor assay (VCA) to assess the skin blanching response has also been used. However, the reported skin blanching response data were often based on a single visual reading and lack information on the dose (amount/quantity) or dose duration. Although several lists classifying potencies of various topical corticosteroid products have been published, the inherent potencies of topical corticosteroid raw materials used as active pharmaceutical ingredients (APIs) have not been investigated. The objective was to rank the inherent potencies of topical corticosteroid APIs and to standardize dosing such that the relevant compounds could be compared on a normalized molar basis. The potencies of clobetasol propionate, halcinonide, mometasone furoate, and fluocinolone acetonide were compared using the resulting
Identifiants
pubmed: 34575532
pii: pharmaceutics13091456
doi: 10.3390/pharmaceutics13091456
pmc: PMC8466269
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Biopharmaceutics Research Institute, Rhodes University, Grahamstown, South Africa
ID : BRI Grant No. KZ2/16
Commentaires et corrections
Type : ErratumIn
Références
Health Technol Assess. 2004 Nov;8(47):iii,iv, 1-120
pubmed: 15527669
Arch Dermatol. 1968 Apr;97(4):407-10
pubmed: 4966856
Eur J Pharm Biopharm. 2008 Mar;68(3):453-66
pubmed: 17826047
J Dermatolog Treat. 2006;17(3):133-5
pubmed: 16854751
J Am Acad Dermatol. 1989 May;20(5 Pt 1):791-6
pubmed: 2715430
Clin Pharmacol Ther. 1999 Oct;66(4):346-57
pubmed: 10546918
Drug Intell Clin Pharm. 1988 May;22(5):412-5
pubmed: 3391112
Exp Dermatol. 2015 May;24(5):393-5
pubmed: 25707534
Br J Dermatol. 1985 Oct;113(4):502-3
pubmed: 4063187
J Dermatol. 2006 Oct;33(10):684-91
pubmed: 17040497
Arch Dermatol. 1972 Dec;106(6):825-7
pubmed: 4639246
Pediatr Dermatol. 1996 May-Jun;13(3):239-45
pubmed: 8806127
Arch Dermatol. 1989 Nov;125(11):1509-11
pubmed: 2817915
J Am Acad Dermatol. 2006 Jan;54(1):1-15; quiz 16-8
pubmed: 16384751
J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):458-62
pubmed: 2212144
Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395
pubmed: 33151290
Am Fam Physician. 2009 Jan 15;79(2):135-40
pubmed: 19178066
Arch Dermatol. 1970 May;101(5):531-7
pubmed: 5444076
Arch Dermatol. 1985 Jan;121(1):63-7
pubmed: 3881088
Int J Dermatol. 1992 Oct;31 Suppl 1:38-40
pubmed: 1428467
Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53
pubmed: 7032803
Br J Dermatol. 1981 Feb;104(2):179-83
pubmed: 7011356
Arch Dermatol. 1964 May;89:741-6
pubmed: 14122107
Br J Dermatol. 1971 Oct;85(4):381-7
pubmed: 5125641